L’essai de phase 3 Zenith, chez des adultes à haut risque atteints d’hypertension artérielle pulmonaire (HTAP) et recevant la ...

researchers say Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran "The implementation of this technology is expected to enhance the management of chronic kidney ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA ...

The potential advantage of that is unclear for now, as Amgen has suggested, for example, that lepodisiran could be effective even if dosed as infrequently as once per year. AZ said adding ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

A new FDA-approved ATTR-CM treatment is giving new hope to patients — especially older Black Americans who are at high risk ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

(CercleFinance.com) - La société biopharmaceutique britannique Alchemab a annoncé mardi la signature d'un accord de licence avec l'américain Eli Lilly portant sur un nouveau traitement contre ...